Consecuencias clínicas y económicas de la combinación de metformina con inhibidores de la dipeptidilpeptidasa en pacientes con diabetes tipo 2

Mainar, Antoni Sicras; Suárez, C. Roldán; Ramos, B; Artieda, Ruth Navarro; Nolla, Jordi Ibáñez

doi:10.1016/j.rce.2013.06.003

Cited by 13 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, when patients receiving SITA were compared with those receiving SU or TZD, the SITA-treated patients showed an improved persistence and adherence to treatment, as was also documented in another observational study performed in Spain. 29 This is a relevant clinical point since patient compliance, adherence, and persistence in maintaining therapeutic treatment is a complex situation that includes patient and treatment regimen factors that may ultimately provide a barrier to medication adherence. 30 An average estimate of patient nonadherence is 32.5% in patients with diabetes, in spite of data from clinical trials that showed that pharmacological treatment reduces long-term complications.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

Esposti¹,

Saragoni²,

Buda³

et al. 2014

CEOR

View full text Add to dashboard Cite

ObjectivesTo compare clinical outcomes and health care costs across three cohorts of uncontrolled diabetic patients who initiated treatment with one of the following: sulphonylureas (SU), thiazolidinediones (TZD) or sitagliptin (SITA).Materials and methodsWe performed a retrospective study based on a linkage between administrative and laboratory databases maintained by three Italian local health units. The index period ranged from July 2008–June 2010. Patients were treatment-naïve to either SU, TZD, or SITA, but they were already treated with other oral hypoglycemic agents. Demographics and clinical characteristics were assessed at baseline. Adherence was measured by the medication possession ratio and adherent was defined as a patient with a medication possession ratio of 80% or greater. We used a Poisson regression model to estimate the risk ratios for disease-related hospitalizations that occurred during the 18-month follow-up period. The total annual costs included all the pharmacological treatments and the direct costs due to hospitalizations and outpatient services.ResultsWe identified 928 patients treated with SU, 330 patients treated with TZD, and 83 patients treated with SITA. SITA patients were significantly younger and with fewer previous hospital discharges. The baseline mean glycated hemoglobin level was 8.1% for SU, 8.0% for TZD, and 8.3% for SITA patients. SITA-naïve patients were more adherent than the SU- and TZD-naïve patients (79.5% versus 53.2% and 62.8%, respectively; P<0.001). The SU and TZD group showed a significant increased risk of disease-related hospitalizations compared with the SITA group (the unadjusted rate was 10.42 and 7.16 per 100 person-years versus 1.64 per 100 person-years, P=0.003; compared with SU, the adjusted incidence rate ratio for SITA was 0.21, P=0.030). The total annual costs per patient were €972 for SITA, €706 for SU, and €908 for those treated with TZD.ConclusionUncontrolled diabetic patients who initiated – as a second-line therapy in addition to metformin – treatment with SITA, compared to those who initiated treatment with SU or TZD, showed a reduced risk of disease-related hospitalizations. The total annual costs per patient were not significantly different among the three groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

Esposti¹,

Saragoni²,

Buda³

et al. 2014

CEOR

View full text Add to dashboard Cite

show abstract

“…The unit costs used in the study in 2011 (EUR). The tariffs were obtained from the cost analytical accounting, except for medications whose cost was obtained using the retail price [15]. Description, tariff: medical visits, primary health care €23.19, hospitalization visits €104.41, emergency room €117.53; hospitalization (1 day) €320.90; laboratory tests €22.30, conventional radiology €18.50, and diagnostic/therapeutic tests €37.12.…”

Section: Methodsmentioning

confidence: 99%

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients

Sicras‐Mainar

Navarro‐Artieda

2015

Diabetes Metab J

View full text Add to dashboard Cite

BackgroundTo evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice.MethodsAn observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years.ResultsWe included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001.ConclusionDespite the limitations of the study, patients with renal impairment treated with DPP-4 inhibitors had better metabolic control, lower rates (association) of hypoglycaemia, and lower health costs for the Spanish national health system.

show abstract

Observational studies with type 2 diabetes mellitus treatments in Spain: A systematic literature review

Díaz

Dilla

Reviriego

2019

Endocrinología, Diabetes y Nutrición (English ed.)

View full text Add to dashboard Cite

Consecuencias clínicas y económicas de la combinación de metformina con inhibidores de la dipeptidilpeptidasa en pacientes con diabetes tipo 2

Cited by 13 publications

References 25 publications

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients

Observational studies with type 2 diabetes mellitus treatments in Spain: A systematic literature review

Contact Info

Product

Resources

About